Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 5Prostatic Neoplasms 3Skin Neoplasms 2Precancerous Conditions 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Stomach Neoplasms 1Sarcoma, Ewing 1Osteosarcoma 1Non-melanoma Skin Cancer 1Neoplasms 1Medulloblastoma 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Temozolomide 10Cyclophosphamide 10Vincristine 9Etoposide 6Doxorubicin 6Irinotecan 5palbociclib 4cabozantinib 4Topotecan 4Melphalan 4Magnetic Resonance Spectroscopy 4X-Rays 3Sirolimus 3Phantoms, Imaging 3Ifosfamide 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2ganitumab 2cixutumumab 2Vemurafenib 2Trabectedin 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Ewing × Eflornithine × Clear all
NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡